CRISPR-Cas9–based treatment of myocilin-associated glaucoma

CRISPR-Cas9–based treatment of myocilin-associated glaucoma

Primary open-angle glaucoma (POAG) is a leading cause of irreversible vision loss worldwide, with elevated intraocular pressure (IOP) a major risk factor. Myocilin (MYOC) dominant gain-of-function mutations have been reported in ∼4% of POAG cases. MYOC mutations result in protein misfolding, leading...

Full description

Bibliographic Details
Main Authors: Jain, Ankur, Zode, Gulab, Kasetti, Ramesh B., Sharma, Tasneem P., Bugge, Kevin, Searby, Charles C., Fingert, John H., Clark, Abbot F., Sheffield, Val C., Ran, Fei, Yan, Winston Xia, Zhang, Feng
Other Authors: Institute for Medical Engineering and Science
Format: Article
Published: National Academy of Sciences (U.S.) 2018
Online Access:http://hdl.handle.net/1721.1/115175
https://orcid.org/0000-0002-3067-479X
https://orcid.org/0000-0003-2782-2509

Internet

http://hdl.handle.net/1721.1/115175
https://orcid.org/0000-0002-3067-479X
https://orcid.org/0000-0003-2782-2509

Similar Items